The DTWD1 Knockout A-549 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal population of A-549 human lung adenocarcinoma epithelial cells harboring targeted disruptions in the DTWD1 gene. This polyclonal knockout pool allows the study of DTWD1 loss-of-function without the biases of clonal selection, capturing a spectrum of edits at the target locus. The use of CRISPR/Cas9 enables efficient gene disruption, generating a versatile model for functional genomics in a lung cancer context.
The A-549 cell line, derived from a human alveolar basal epithelial adenocarcinoma, is a well-established model of type II pulmonary epithelial cells. It is widely used in respiratory disease research, cancer biology, and drug metabolism studies due to its capacity to form monolayers and its characteristic oncogenic mutations, such as in KRAS. The A-549 background provides a clinically relevant platform for exploring gene function in lung adenocarcinoma, combining ease of genetic manipulation with physiologically meaningful epithelial traits.
DTWD1 encodes a protein featuring a DTW domain, a structural motif associated with tRNA binding. Accordingly, DTWD1 is predicted to participate in tRNA modification or RNA processing, though its exact biochemical activity and substrates remain unknown. No upstream regulators, downstream effectors, or interacting partners have been identified, and DTWD1 has not been integrated into known signaling networks. The protein’s molecular mechanism is therefore uncharacterized, but its domain suggests a role in modulating tRNA structure and function, potentially influencing translational control.
Introducing DTWD1 knockout in A-549 cells permits the investigation of tRNA modification biology in lung adenocarcinoma. Given the significance of translational deregulation in cancer, loss of a putative tRNA modifier could impact cell proliferation, survival, or invasive properties. This model may help determine whether DTWD1 contributes to the malignant phenotype of A-549 cells and whether its absence sensitizes cells to specific stresses or drugs, thereby uncovering new insights into RNA-based cancer vulnerabilities.
Typical research applications include validation of knockout by Western blotting and RT-qPCR, transcriptome-wide analysis via RNA-seq, and phenotypic assays for proliferation, migration, and invasion. Flow cytometry can assess apoptosis and cell cycle alterations, while immunofluorescence informs on subcellular localization. This product supports investigations into the fundamental roles of DTWD1 and the DTW domain family, as well as translational studies targeting RNA modifications in cancer. For technical support, contact Ascent Research.
